Pharnext Announces Encouraging Data from Open ‐ Label Phase 3 Extension Study of PXT3003
Pharnext Announces Encouraging Data from Open ‐ Label Phase 3 Extension Study of PXT3003
Continue Reading
Pharnext Announces Encouraging Data from Open ‐ Label Phase 3 Extension Study of PXT3003
Continue ReadingCRISPR/Cas9 Treatment Can Improve Nerve Functioning in Mouse Model of CMT1A, Study Suggests
Continue Reading2019.08.30_PXT3003_US_FDA_EN
Continue ReadingNantes, France – May 15th, 2019 InFlectis BioScience SAS, a drug discovery company committed to the development of innovative therapeutics […]
Continue ReadingThis brings us inline with the European CMT Federation of which we are a founding member organisation. It also prevents […]
Continue ReadingImplanting stem-derived Schwann-like cells into mice with Charcot-Marie-Tooth type 1A improved neuron function, leading to better motor activity and nerve […]
Continue ReadingLast Updated: Wednesday 8th January, 2020